MedTrace Logo

Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP

NCT05669534 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2025-03-27

No results posted yet for this study

Summary

The investigators will conduct an optimization trial among N=256 PWID newly started on medication for opioid use disorder and Pre-Exposure Prophylaxis (PrEP) to assess the performance of four intervention components (Attention, Executive Functioning, Memory, and Information Processing) aimed at enhancing the ability of PWID on MOUD to process and utilize HIV prevention content, leading to improvements in HIV prevention information, motivation, behavioral skills, and behaviors (IMB).

Conditions

Interventions

BEHAVIORAL

community-friendly health recovery program

Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.

DRUG

Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis

Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Sponsors & Collaborators

  • University of Connecticut

    lead OTHER

Principal Investigators

  • Michael Copenhaver, PhD · University of Connecticut

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2027-01-31
Completion
2027-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669534 on ClinicalTrials.gov